AstraZeneca and Sino Biopharma Ink $1.9 Billion Respiratory Drug Deal

Key Facts

In a move reflecting the accelerating pace of international collaboration in the biotech sector, Sino Biopharmaceutical has entered into a strategic licensing agreement with the British giant AstraZeneca. Under the terms of the deal, the Chinese firm granted AstraZeneca the rights to develop and commercialize a drug targeting chronic respiratory diseases in global markets outside of China. The agreement includes upfront and potential milestone payments totaling up to $1.9 billion.

This partnership comes as AstraZeneca seeks to bolster its respiratory portfolio, a segment that contributed approximately $6.4 billion to the company's revenue in 2023 according to its annual reports. This deal positions Sino Biopharma strongly among Chinese pharmaceutical firms exporting innovation, as the deal value exceeds the average for similar licensing agreements in the sector. In comparison to peers, shares of GSK, a primary rival in the asthma treatment space, have shown stable movement as AstraZeneca expands its pipeline per market data.

Regarding market performance, AstraZeneca (AZN.L) shares closed at 14,364 pence as of July 7, 2026, while Sino Biopharma (1177.HK) stood at HKD 5.05 at the close of July 6, 2026. Investors are now monitoring clinical trial updates for this drug as a future catalyst, alongside upcoming manufacturing PMI data from China to gauge the broader business environment for pharmaceutical manufacturers in the region.